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161Tb (30 MBq/nmol) and investigated in vitro using 
somatostatin receptor-positive AR42J rat tumor cells. 
Viability and survival assays were performed in vitro. 
Results: In vivo application of 161Tb-folate (10 MBq) resulted 
in a reduced KB tumor growth and, as a consequence, in an 
increased survival time (54 d) of mice compared to those 
treated with 177Lu-folate (10 MBq, 35 d) [3]. Based on BUN 
and creatinine plasma values and histological investigations 
of renal tissues, 161Tb-folate did not result in more severe 
damage to the kidneys than 177Lu-folate, however. In vitro 
investigations with 161Tb-DOTATOC and 161Tb-DOTATOC-NLS 
revealed comparable uptake into AR42J cells, but 
externalization of 161Tb-DOTATOC-NLS was lower (~25%) than 
for 161Tb-DOTATOC (~55%) after 6 h. After 2 h of incubation 
the fraction of internalized 161Tb-DOTATOC-NLS, which was 
localized in the nucleus (~3%), was significantly higher than 
the fraction of 161Tb-DOTATOC (<0.5%). AR42J cell killing 
after application of 161Tb-DOTATOC-NLS was more effective 
(IC50 ~1.5 MBq/mL) than after treatment with 161Tb-
DOTATOC (IC50 ~8 MBq/mL). 
Conclusion: Due to additional Auger electron emission, 161Tb 
appears to be more effective for tumor treatment than 177Lu. 
The effect caused by Auger electrons was found to be more 
powerful if the radioconjugate targets the cellular nucleus by 
means of a NLS. Interestingly, kidney damage was not 
enhanced after therapy with 161Tb compared to the 
treatment with 177Lu. Based on these findings, 161Tb has a 
great potential to be used in future clinical practice as it may 
kill single cancer cells and cell clusters more efficiently than 
177Lu without causing additional side effects. 
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A triple GEM detector with a 55 μm pitch pixelated ASIC for 
the readout has been used at CNAO in Pavia for a detailed 
measurements of energy deposition inside a water phantom. 
The detector was operated with a gas mixture of Ar CO2 CF4 
at a moderate gain and the measurements were performed 
with a beam of 120 MeV protons and 330 MeV/u Carbon ions. 
The energy deposition was measured at different positions in 
depth allowing a 3D reconstruction of the beam inside the 
phantom as shown in the figure. A small number of single 
event upsets in the pixel readout appear only in the Bragg 
peak and the DAQ can recover them for each acquisition. A 
detailed simulation was performed with GEANT4 and it was 
found in good agreement with the experimental data. 
The future uses and upgrade of this device, including its 
potential application in microdosimetry, are discussed. 
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The need for an open-access biomedical research facility was 
first raised by the scientific community at the 2010 Physics 
for Health workshop, where CERN was asked to take the lead 
on this initiative.  
In 2012, a brainstorming meeting evaluated the possibility of 
modifying the existing CERN Low Energy Ion Ring (LEIR) 
accelerator to establish such an infrastructure.  The medical 
and radiobiological communities united in broad agreement 
on the need for such a dedicated research facility. 
The Biomedical facility at CERN (OPEN-MED) would create an 
open collaborative biomedical research infrastructure. By 
sharing the facility internationally, more rapid progress can 
be made by: 
• Complementary collaboration with leading 
universities, research facilities and industry  
• Comprehensively investigate complex physical and 
biological parameters that control radiation cell 
killing efficiency under highly controlled 
conditions.  
• Provide accurate data for the modelling of 
radiation effects for proton and ion beam clinical 
applications 
• Study comparative beam ballistics and dosimetry in 
phantoms and so improve predicted physical dose 
distributions.    
• Provide a range of beams and infrastructure for 
developing new instrumentation for detection and 
imaging. 
• Provide adequate beam time  
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It is essential that we develop a better understanding of how 
radiation interacts with cells at the cellular and molecular 
level, both to understand the nature of radiation-induced 
cancers resulting from radio-therapy and to devise more 
effective treatments, especially combining radiation therapy 
with other treatment modalities. Key to this is a more 
complete understanding of the underpinning radiobiology. 
OPEN-MED would aim to provide a coherent homogeneous 
database which is now necessary to take advantage of the 
recent rapid advances in cellular and molecular biology, 
using a wide range of human derived cells and eventually 
tissues. This requires advanced computational infrastructure 
which is also available at CERN.  
Therefore it is proposed to convert the existing accelerator 
LEIR at CERN, which is used typically for a few months each 
year for pre-accelerating heavy ions (mostly lead) for the 
Large Hadron Collider, by adding a new set of ion sources 
(protons, light ions such as lithium, boron and carbon and 
perhaps heavier ions like oxygen and neon), a new extracted 
beam line and a radiobiology facility dedicated to 
radiobiology experiments for at least eight months of each 
year. 
Unique features of the facility would be:   
• A range of ions  from proton to oxygen at the first  
stage, but using higher energies and other ions   
relevant  for  space  radiobiology  in a later second 
phase 
• Versatile energy, charge, mass, beam switching and 
pulsed capabilities 
• Versatile biological end station for optimal sample 
configuration and analysis 
• Beam time availability for 8 months each year 
• Internationally shared expertise 
 
The facility would enhance research training standards with 
benefits to medical physics, radiation biology, radiation 
oncology and radioprotection. The data acquired would lead 
to an improved understanding of the technical requirements 
for the design of future accelerators and associated 
technology for cancer therapy. This strategy would provide 
the capability for a systematic assay of radiobiological 
properties, and be complementary to the clinical research in 
hospitals and other places, where in vivo and specific trials 
translating this work into clinical use can be performed. 
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Purpose: To present novel modeling results showing the 
feasibility of proton pencil beam scanning (PBS) in the 
presence of an MRI scanner. This is a key requirement of 
potential future MRI Guide Proton Therapy systems [1].  
Materials and Methods: Magnetic and Monte Carlo modelling 
of a 1 T split-bore MRI system[2] coupled with a proton pencil 
beam scanning assembly (Universal Head, IBA, Belgium) were 
performed (figure 1a). The impact of an active scanning PBS 
assembly on the MRI imaging potential was assessed as well 
as the impact of the MRI fringe field on performance of the 
PBS system. 
Results: With the PBS assembly present the MR imaging field 
non-uniformity increased from 7 parts per million (ppm) to 55 
ppm which is correctable via conventional shimming. With 
full scanning currents (active mode) the non-uniformity was 
55+/-2.5 ppm. Thus MR image quality is expected to be 
maintained with dynamic scanning. Monte Carlo modelling 
further predicts that the MRI fringe field does not perturb the 
inherent magnetic deflection process of the PBS assembly. 
However once scanned, the pencil beams undergo an energy 
dependent and complex 3D deflection as they pass through 
the MRI fringe field[1]. Therefore a detailed calibration 
process is required to correct for each pencil beam so that 
PBS can be performed accurately. This correction process will 
be integrated in the plan optimization process to account for 
the magnetic field within a patient[3,4]. As an example, the 
path of a 170 MeV pencil beam is shown in a water phantom, 
and then what is required to obtain the same Bragg-peak 
with the fringe field (figure 1b and 1c). Both energy and 
direction changes are required. 
 
Figure1. (a) Layout of the MRI Guided Proton Therapy system 
showing the MRI scanner, patient location, and PBS assembly.  
(b) Path of a 170 MeV proton pencil beam (blue) with no MRI 
fringe field entering a water phantom.  (c) Path of a steered 
173 MeV pencil beam passing through the fringe field. Both of 
these beams have a Bragg-peak at 190 mm depth on the 
beam central axis. Secondary electrons are shown in red. 
 
Conclusions: PBS in MRI-guided proton therapy appears 
feasible with current methods. Calibration of the inherent 
fringe field deflections of proton beams will be an essential 
part of the commissioning process. Future work will include 
modeling of the expected performance of beam monitoring 
devices in the presence of MRI fringe fields. 
 
